Bone marrow stromal cells attenuate sepsis via prostaglandin E-2-dependent reprogramming of host macrophages to increase their interleukin-10 production

作者：Nemeth Krisztian; Leelahavanichkul Asada; Yuen Peter S T; Mayer Balazs; Parmelee Alissa; Doi Kent; Robey Pamela G; Leelahavanichkul Kantima; Koller Beverly H; Brown Jared M; Hu Xuzhen; Jelinek Ivett; Star Robert A; Mezey Eva^*

来源：Nature Medicine, 2009, 15(1): 42-49.

DOI：10.1038/nm.1905

Sepsis causes over 200,000 deaths yearly in the US; better treatments are urgently needed. Administering bone marrow stromal cells (BMSCs-also known as mesenchymal stem cells) to mice before or shortly after inducing sepsis by cecal ligation and puncture reduced mortality and improved organ function. The beneficial effect of BMSCs was eliminated by macrophage depletion or pretreatment with antibodies specific for interleukin-10 (IL-10) or IL-10 receptor. Monocytes and/or macrophages from septic lungs made more IL-10 when prepared from mice treated with BMSCs versus untreated mice. Lipopolysaccharide (LPS)-stimulated macrophages produced more IL-10 when cultured with BMSCs, but this effect was eliminated if the BMSCs lacked the genes encoding Toll-like receptor 4, myeloid differentiation primary response gene-88, tumor necrosis factor (TNF) receptor-1a or cyclooxygenase-2. Our results suggest that BMSCs ( activated by LPS or TNF-alpha) reprogram macrophages by releasing prostaglandin E-2 that acts on the macrophages through the prostaglandin EP2 and EP4 receptors. Because BMSCs have been successfully given to humans and can easily be cultured and might be used without human leukocyte antigen matching, we suggest that cultured, banked human BMSCs may be effective in treating sepsis in high-risk patient groups.

• 出版日期2009-1